The Ophthalmic Drugs Market: 2017 – 2030 Opportunities, Challenges, Strategies & Forecasts​


Release Date: December 2016
Number of Pages: 267
Number of Tables and Figures: 45

Synopsis: As a higher percentage of the global population lives longer, age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration are on the rise. In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.

Although surgery is the only option for the treatment of certain ophthalmic conditions such as cataracts, ophthalmic drugs continue to account for the highest percentage of spending within the wider market for ophthalmic products. Expected to surpass $30 Billion in global spending by the end of 2020, ophthalmic drugs remain the preferred approach to treat common eye disorders, ranging from dry eye syndrome to more complicated conditions such as glaucoma and macular degeneration. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with a number of novel drugs in late-stage development.
The “Ophthalmic Drugs Market: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the ophthalmic drugs ecosystem including application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for ophthalmic drugs from 2017 through to 2030. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 25 leading countries.
​
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Expected to surpass $30 Billion in global spending by the end of 2020, ophthalmic drugs remain the preferred approach to treat common eye disorders, ranging from dry eye syndrome to more complicated conditions such as glaucoma and macular degeneration.
  • The future pipeline of ophthalmic drugs is promising as drug developers continue to invest heavily in novel therapeutic development programs.
  • New R&D programs are primarily focused on anti-inflammatory agents, long-acting anti-VEGF treatments, ROCK (Rho Kinase) inhibitors, adenosine agonists, NO (Nitric Oxide) donors, combination therapies, complement factor inhibitors and cell therapies, among other areas.
  • In a bid to improve patient compliance and reduce the burden of frequent patient visits, drug developers are investing in the development of convenient and potentially cost-effective delivery routes, including oral delivery, intravitreal implants and dissolvable intracanalicular depots.

Topics Covered:
The report covers the following topics:
  • Ophthalmic drugs ecosystem
  • Market drivers and barriers
  • Eye disorders, application areas and key trends
  • Analysis of key drug classes and leading ophthalmic drugs
  • Future drug development pipeline
  • Ophthalmic drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of over 120 leading ecosystem players, including ophthalmic drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2017 till 2030

Forecast Segmentation
  • Market forecasts are provided for each of the following submarkets and their subcategories:
    • Therapeutic Category
      • Anti-Infectives
      • Allergy & Anti-Inflammatory
      • Dry Eye
      • Glaucoma
      • AMD
      • Diabetic Eye Disease
      • Other Disorders
    • Regional Markets
      • Asia Pacific
      • Europe
      • Middle East & Africa
      • North America
      • Latin & Central America
    • Country Markets
      • Brazil
      • Canada
      • China
      • Egypt
      • France
      • Germany
      • Greece
      • India
      • Israel
      • Italy
      • Japan
      • Mexico
      • Netherlands
      • Poland
      • Portugal
      • Russia
      • Saudi Arabia
      • South Africa
      • South Korea
      • Spain
      • Switzerland
      • Taiwan
      • Turkey
      • UK
      • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the ophthalmic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2020 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of​ growth?
  • What are the prospects of new drug delivery technologies, such as nanotechnology and iontophoresis?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should ophthalmic drug manufacturers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
4D Molecular Therapeutics
Abbott Laboratories
Abbott Medical Optics
AbbVie
ACADIA Pharmaceuticals
Acorn Biomedical
Adenovir Pharma
Adverum Biotechnologies
Aegerion Pharmaceuticals
Aerie Pharmaceuticals
Aerpio Therapeutics
Akorn Pharmaceuticals
Alcon
Alimera Sciences
Allegro Ophthalmics
Allergan
Altacor
Alteogen
Amakem Therapeutics
Amgen
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Astellas Pharma
Avizorex Pharma
Bausch & Lomb
Bayer
Benitec Biopharma
Bicycle Therapeutics
BIKAM Pharmaceuticals
BioAxone Biosciences
BioDiem
BioLineRx
BioTime
BMS (Bristol-Myers Squibb)
Can-Fite BioPharma
Catalyst Biosciences
CDI (Cellular Dynamics International)
Cell Cure Neurosciences
Chengdu Kanghong Biotech
Chugai Pharmaceuticals
Coherus BioSciences
Colby Pharmaceutical Company
D.Western Therapeutics Institute
Dompé
Eleven Biotherapeutics
Envisia Therapeutics
ESBATech
EyeCRO
EyeGate Pharmaceuticals
Foresight Biotherapeutics
Formycon
Fujifilm Holdings
Galapagos
Gene Signal
Genentech
Gensight Biologics
Glycadia Pharmaceuticals
GrayBug Vision
GSK (GlaxoSmithKline)
Healios
Hebrew University of Jerusalem
Helvetic BioPharma
Herantis Pharma
Hi-Tech Pharmacal
Icon Bioscience
Innovations in Sight
Inotek Pharmaceuticals
InSite Vision
Intas Pharmaceuticals
Johns Hopkins University
Kala Pharmaceuticals
KalVista Pharmaceuticals
Kissei Pharmaceutical
Kowa Company
Kubota Pharmaceutical Holdings
Lexicon Pharmaceuticals
Lpath
Lubris BioPharma
Lux Biosciences
MacuCLEAR
Mati Therapeutics
Merck and Co.
Microbot Medical
Mimetogen Pharmaceuticals
Mitotech
Molecular Partners
MorphoSys
Nektar Therapeutics
NEMUS Bioscience
NeuMedics
Neurotech Pharmaceuticals
Neusentis
Nicox
NovaBay Pharmaceuticals
Novaliq
Novartis
Novelion Therapeutics
NovelMed Therapeutics
Ocata Therapeutics
OcuCure Therapeutics
Ocular Therapeutix
Ohr Pharmaceutical
Omeros
ONL Therapeutics
OphthaliX
Ophthotech
OPKO Health
Ora
Otsuka Holdings
Otsuka Pharmaceutical
Oxford BioMedica
PanOptica
Parion Sciences
Peregrine Ophthalmic
Perrigo Company
Pfenex
Pfizer
Premacure
pSivida
Quark Pharmaceuticals
Regeneron Pharmaceuticals
RegeneRx Biopharmaceuticals
RetroSense Therapeutics
Rigel Pharmaceuticals
Rinat
Roche Holding (F. Hoffmann-La Roche)
R-Tech Ueno
RXi Pharmaceuticals
Sandoz
Sanofi
Santen Pharmaceutical Company
Santo Holding
SARcode Bioscience
SciFluor Life Sciences
Seikagaku Corporation
Senju Pharmaceutical
Shire
Stealth BioTherapeutics
Stemedica Cell Technologies
Sucampo Pharmaceuticals
Sun Pharma (Sun Pharmaceutical Industries)
Sylentis
Teva Pharmaceutical Industries
ThromboGenics
TRACON Pharmaceuticals
Tyrogenex
U.S. FDA (Food and Drug Administration)
Valeant Pharmaceuticals International
Ventana Medical Systems
Vision Medicines
Wakamoto Company
Xbrane Biopharma
Yissum Research Development Company